SCHEMBL1998783

SCHEMBL1998783

Cc1ccc2c(c1)c(C(=O)c1nc(-c3cccnn3)no1)c(Cl)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TP53 P04637 3/20 0.33
NPSR1 Q6W5P4 3/20 0.33
CYP2C9 P11712 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
ALOX12 P18054 1/20 0.33
FAAH O00519 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
VDR P11473 1/20 0.32
PTGDR2 Q9Y5Y4 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
PTGS1 P23219 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2004741 0.94 FAAH (0.38) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL2002614 0.91 PLA2G2A (0.37) LMNASMN1; SMN2TP53CYP2C9MEN1
SCHEMBL2003771 0.90 LMNA (0.41) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL2008317 0.90 FAAH (0.41) LMNATP53CYP2C9MEN1KMT2A
SCHEMBL2001286 0.90 GRM5 (0.41) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL2004856 0.88 LMNA (0.38) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL1999496 0.87 LMNA (0.35) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL2004511 0.86 LMNA (0.41) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL2003213 0.86 MAPT (0.40) LMNASMN1; SMN2TP53NPSR1CYP2C9
SCHEMBL2003553 0.86 GSK3B (0.42) LMNASMN1; SMN2TP53NPSR1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 LMNA 3450/4885SMN1; SMN2 3581/4885TP53 2579/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT LMNA 4536/4885SMN1; SMN2 4663/4885TP53 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.